Study of Crizotinib for ROS1 and MET Activated Lung Cancer
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has
spread to other parts of the body) non-small cell lung cancer with a mutation (change) in
genes called ROS1 or MET. The purpose of this study is to look at how effective crizotinib is
at treating ROS1 or MET mutated non-small cell lung cancer.
Crizotinib, also called XALKORI, is a chemotherapy drug that is currently approved for the
treatment of ALK- or ROS1- positive advanced non-small cell lung cancer.